A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

G Descamps; P Gomez-Bougie; C Venot; P Moreau; R Bataille; M Amiot

doi:10.1038/sj.bjc.6604839

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

Br J Cancer. 2009 Jan 27;100(2):366-9. doi: 10.1038/sj.bjc.6604839.

Authors

G Descamps¹, P Gomez-Bougie, C Venot, P Moreau, R Bataille, M Amiot

Affiliation

¹ Centre de recherches en Cancérologie Nantes/Angers, INSERM, UMR 892, UFR Médecine et Techniques Médicales, Université de Nantes, Nantes Atlantique Universités, Nantes, France.

Abstract

The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / pharmacology*
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Apoptosis / immunology
Boronic Acids / pharmacology*
Bortezomib
Caspase 3 / metabolism
Cell Proliferation / drug effects
Enzyme Activation / drug effects
Humans
Leukocyte Common Antigens / metabolism*
Multiple Myeloma / drug therapy
Multiple Myeloma / immunology
Multiple Myeloma / pathology*
Proto-Oncogene Proteins c-bcl-2 / metabolism
Pyrazines / pharmacology*
Receptor, IGF Type 1 / immunology*
Tumor Cells, Cultured

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Boronic Acids
PMAIP1 protein, human
Proto-Oncogene Proteins c-bcl-2
Pyrazines
Bortezomib
Receptor, IGF Type 1
Leukocyte Common Antigens
Caspase 3